Specify a stock or a cryptocurrency in the search bar to get a summary
Reneo Pharmaceuticals Inc
RPHMReneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California. Address: 18575 Jamboree Road, Irvine, CA, United States, 92612
Analytics
WallStreet Target Price
2.25 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures RPHM
Dividend Analytics RPHM
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RPHM
Stock Valuation RPHM
Financials RPHM
Results | 2019 | Dynamics |